Privosegtor
Privosegtor is an investigational new drug that is being evaluated by Oculis Pharma for the treatment of optic neuritis. It is a serine/threonine-protein kinase SGK2 activator that is claimed to have neuroprotective properties.
Beyond's analysis on Privosegtor
- — Oculis strengthens its neuro-ophthalmology pipeline by acquiring Accure Therapeutics' lead asset Privosegtor, consolidating its position in a niche therapeutic area
- — Oculis acquires lead neuro-ophthalmology candidate Privosegtor from Accure Therapeutics to solidify its emerging leadership in the field
- — Oculis secures Privosegtor asset from Accure Therapeutics, strengthening its neuro-ophthalmology pipeline and market positioning